About Glycine amidinotransferase, mitochondrial
Glycine amidinotransferase, mitochondrial (GATM) is a protein
from Homo sapiens identified by UniProt accession
P50440, 423 residues long.
MolForge cross-references it against 0 known binders and
243 disease associations.
Target properties
| Protein name | Glycine amidinotransferase, mitochondrial |
| UniProt accession | P50440 |
| Gene | GATM |
| Organism | Homo sapiens |
| Length | 423 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (243)
Diseases linked to this target (Open Targets).
- Arginine:glycine amidinotransferase deficiency · score 0.82
- AGAT deficiency · score 0.80
- Fanconi renotubular syndrome 1 · score 0.74
- creatinine measurement · score 0.52
- glomerular filtration rate · score 0.41
- chronic kidney disease · score 0.36
- serum metabolite measurement · score 0.34
- neurodegenerative disease · score 0.33
- urinary albumin to creatinine ratio · score 0.32
- appendicular lean mass · score 0.29
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P50440-F1 | alphafold | PREDICTED | 89.65 | — |
Amino-acid sequence (423 residues)
MLRVRCLRGG SRGAEAVHYI GSRLGRTLTG WVQRTFQSTQ AATASSRNSC AADDKATEPL PKDCPVSSYN EWDPLEEVIV GRAENACVPP FTIEVKANTY EKYWPFYQKQ GGHYFPKDHL KKAVAEIEEM CNILKTEGVT VRRPDPIDWS LKYKTPDFES TGLYSAMPRD ILIVVGNEII EAPMAWRSRF FEYRAYRSII KDYFHRGAKW TTAPKPTMAD ELYNQDYPIH SVEDRHKLAA QGKFVTTEFE PCFDAADFIR AGRDIFAQRS QVTNYLGIEW MRRHLAPDYR VHIISFKDPN PMHIDATFNI IGPGIVLSNP DRPCHQIDLF KKAGWTIITP PTPIIPDDHP LWMSSKWLSM NVLMLDEKRV MVDANEVPIQ KMFEKLGITT IKVNIRNANS LGGGFHCWTC DVRRRGTLQS YLD
Explore Glycine amidinotransferase, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets